To find probes for Every Protein, LeadArt has established a unique and growing active probe library (>4000), and has an innovative chemoproteomics automation equipment platform. By combining cutting-edge biotechnology and advanced automation technology, LeadArt is aspired to achieve the first-ever large-scale exploration of the binding between more than 20,000 proteins and active drugs in human history, and establish the world's largest and highest-quality drug-target data, laying the foundation for the development of over 4,000 undruggable targets and new drug discovery.
More details
Automated Chemoproteomics Platform
Chemoproteomics is a new scientific field that integrates chemical synthesis and proteomics technology, aiming to discover and study the protein targets of small molecule compounds (such as drugs, chemical compounds, or metabolites) within complex biological systems, such as living cells, and conduct in-depth research on these target proteins. This field involves a wide range of technologies, including chemical synthesis, mass spectrometry, bioinformatics, and more. LeadArt's independently developed chemoproteomics sample preparation platform enables the simultaneous processing of a large number of samples and plays an important role in promoting large-scale automated chemical proteomics research, high-throughput drug screening, and chemical biology research. With the continuous development and innovation of automation technology, it is believed that the use of automated equipment for chemoproteomics sample preparation will become an increasingly significant research method in the field of chemical drug target identification.
Gain a deeper understanding of sample preparation in chemoproteomics
Target Identification
With the advanced PAL-AfBPP technology, which utilizes photoaffinity labeling, LeadArt is at the forefront of chemoproteomics. This innovative approach allows for the investigation of the biological mechanisms (MoA) of active drugs in live cell systems. By obtaining precise information about drug-protein binding regions, it unveils potential off-target toxicity and identifies novel targets for new indications. Notably, LeadArt's PAL-AfBPP technique achieves these results without the need for protein labeling or modification, preserving the proteins in their native state. Additionally, it enables the enrichment of naturally occurring low-abundance proteins, offering a groundbreaking solution for studying challenging targets.
More details
Live Cell Drug Screening
LeadArt provides drug screening solutions based on living cells for difficult-to-drug and difficult-to-research targets. There is no need to isolate and purify the target protein, and high-throughput drug screening can be performed directly on the protein in living cell models.
Inquiries
Wechat Public
Scan wechat on your phone
QQ: